RAPIDEC® CARBA NP
Rapid, Reliable Test for Carbanemase-Producing Bacteria
High medical value test confirms Carbanemase-producing Gram-negative bacilli in agar cultures with reliable results in under 2 hours. This test is a quick and easy way to control carbapenemase producers and meet diagnostic and screening challenges, improving patient management and controlling HAI.
Disclaimer: Product availability varies by country. Please consult your local bioMérieux representative for product availability in your country.
- Overview
- Specs & Resources
Overview
The Global Burden of Carbapenemase
Rising antimicrobial drug resistance is one of the most urgent challenges facing the field of healthcare today. Carbapenem antibiotics are a last-resort drug used to treat bacterial infections. However, strains of Carbapenem-resistant bacteria, particularly Enterobacteriaceae, are rapidly emerging.
There are 2 types of resistance to Carbapenems:
1. If resistance results from impermeability or efflux, it is not transmissible and there is no need to isolate patients.
2. If resistance is caused by carbapenemase enzyme production, it is transmissible and preventative action is necessary.
Infection caused by carbapenemase producers is therefore very difficult to treat, has a higher rate of mortality, and can easily spread between humans via contact, food, and water – leading to greater risk of outbreaks of healthcare-associated infections (HAI). In Antibiotic Resistance Threats 2019, the CDC classes Carbapenem resistance in its most serious category “urgent threat” meaning it is “an immediate public health threat that requires urgent and aggressive action”1.
Detection of resistance to Carbapenem, particularly when due to transmissible Carbapenemase-producing bacteria, is critical to properly orient antibiotic therapy, implement appropriate isolation measures, and conduct screening. Most methods for detection and confirmation are complicated, costly, and have long time-to-results. Some tests lack sensitivity and specificity, making results less reliable.
All-in-One Solution
RAPIDEC® CARBA NP offers high medical value as a cost-effective, all-in-one solution providing rapid results – between 30 minutes to 2 hours. The test is based on the direct detection of Carbapenem hydrolysis by Carbapenemase-producing bacteria. Therefore, it distinguishes only Carbapenem resistance that is transmissible, avoiding unnecessary patient isolation. With its high specificity and sensitivity (both 97.8%*), the test can contribute to better patient management and controlling the spread of HAI.
RAPIDEC® CARBA NP is rapid and reliable enough to confirm diagnosis and help orient patient treatment, yet economical enough to be used for screening.
- Adaptable to any lab
- Easy to use
- Cost-effective
- Rapid time-to-result
- Manages infection risk
- Reliable, specific, and sensitive
- Discriminates transmissible resistance
*Performance: RAPIDEC® CARBA NP test performance was established at two European sites using 275 collection strains or routinely encountered strains.
Principle
What makes RAPIDEC® CARBA NP different is how it works. It was developed in collaboration with international experts P. Nordmann and L. Poirel, based on the principle they described along with colleague L. Dortet 2,3. The RAPIDEC® CARBA NP test detects Carbapenem hydrolysis by Carbapenemase-producing bacteria: Enterobacterlaes, Pseudomonas aeruginosa, and Acinetobacter baumannii. Hydrolysis acidifies the medium which results in the change in color of the pH indicator – indicating specifically the presence of transmissible Carbapenem resistance.
RAPIDEC® CARBA NP detects (without distinction) all 3 types of produced Carbapenemase:
- Class A: KPC being the main representative
- Class B: Metallo ß-Lactamases (MBL), NDM-1, VIM, and IM
- Class D: OXA Carbapenemases
Ready-to-Use Kit
The ready-to-use RAPIDEC® CARBA NP kit contains all you need to conduct the test in a few easy steps.
1. After bacterial lysis, which enables the extraction of the enzyme, the lysate is added to a detection solution which contains…
2. After incubation, readings are done by visually comparing a control well, starting at 30 minutes, but no more than 2 hours.
Easy Protocols for Both Screening and Diagnostics
References:
1. Antibiotic Resistance Threats in the United States, CDC 2019
2. NORDMANN P., POIREL L., DORTET L. Rapid detection of carbapenemase-producing Enterobacteriaceae. Emerging Infectious Diseases, www.cdc.gov/eid, 2012, vol. 18, n°9, 1503-1507.
3. DORTET L., POIREL L., NORDMANN P. Rapid identification of carbapenemase types using a biochemical test in Enterobacteriaceae and Pseudomonas. Antimicrobial. Agents Chemother., 2012, vol. 56, n°12, 6437-6440.
Specs & Resources
Technical Specifications
- Kit for 10 tests (ref. 415418)
- Kit for 25 tests (ref. 417498)
- Kit for 10 tests (ref. 417824, for the US market)
RAPIDEC® CARBA NP offers the flexibility of two packaging options in ready-to-use kits: one for management of sporadic situations and one for outbreaks.
